Diversified Trust Co Buys 1,955 Shares of Eli Lilly and Company (NYSE:LLY)

Diversified Trust Co boosted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 13.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,615 shares of the company's stock after buying an additional 1,955 shares during the quarter. Diversified Trust Co's holdings in Eli Lilly and Company were worth $13,723,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Beacon Financial Advisory LLC boosted its stake in Eli Lilly and Company by 32.9% in the 1st quarter. Beacon Financial Advisory LLC now owns 372 shares of the company's stock valued at $307,000 after buying an additional 92 shares in the last quarter. Hidden Cove Wealth Management LLC boosted its stake in Eli Lilly and Company by 25.0% in the 1st quarter. Hidden Cove Wealth Management LLC now owns 345 shares of the company's stock valued at $285,000 after buying an additional 69 shares in the last quarter. Tanager Wealth Management LLP acquired a new stake in Eli Lilly and Company in the 1st quarter valued at $259,000. Elite Life Management LLC acquired a new stake in Eli Lilly and Company in the 1st quarter valued at $234,000. Finally, Falcon Wealth Planning boosted its stake in Eli Lilly and Company by 9.6% in the 1st quarter. Falcon Wealth Planning now owns 968 shares of the company's stock valued at $800,000 after buying an additional 85 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on LLY. UBS Group decreased their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Cantor Fitzgerald started coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective for the company. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their price objective for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Finally, HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their price objective for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $1,011.61.

Eli Lilly and Company Trading Down 2.4%

Shares of LLY stock traded down $18.94 on Friday, reaching $776.18. 4,109,419 shares of the stock were exchanged, compared to its average volume of 3,683,590. The stock has a market cap of $735.61 billion, a PE ratio of 63.16, a P/E/G ratio of 1.13 and a beta of 0.40. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. The stock has a 50 day moving average price of $780.19 and a 200 day moving average price of $799.96.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company's revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.58 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.